BroadOak Logo

Grounded in Expertise
Driven by Experience
Proven Value

Since 2006, we have helped life sciences businesses achieve their full potential.

About BroadOak

BroadOak Capital Partners is a life sciences focused, boutique financial institution that provides direct investment through BroadOak Asset Management, and investment banking services through BroadOak Partners, to companies in the life sciences tools, diagnostics, and biopharma services sectors. BroadOak has made investments in more than 50 companies and advised on over 50 successful M&A transactions. 

Life science tools

Growth capital for the development and acceleration of successful businesses.

Services to help management teams optimize sale processes, mergers, acquisitions, and financing.

Our Track Record

Years Experience


Investments & Transactions


Investment Funds Raised


Investment Portfolio Exits


Our Expertise

BroadOak advises and invests in life sciences tools, diagnostics, and services companies. Each sector is highly specialized, and most traditional financial institutions do not have the experience or expertise necessary to provide a true partnership. BroadOak is different. Our in-house expertise, access to proprietary information via deep relationships and networks, and reputation built on 15 years of experience give our portfolio companies and clients results that exceed expectations.

Life Sciences Tools
Market Size: $80B
Instruments and consumables used in therapeutic discovery and development
Market Size: $50B
Diagnostic tests, test components, and instruments for analysis
Biopharma Services
Market Size: $30B
Research, development, and manufacturing services for biopharma companies

Recent Investments & Advisory Transactions

Featured News

BroadOak Capital Partners advised LabConnect on its acquisition of A4P Bio. A4P Bio provides bioanalytical project management solutions

BroadOak Capital Partners advised ZoBio on the sale of the company to Oncodesign Services.  ZoBio is a leading

BroadOak Capital Partners led Pluristyx’s latest fundraising round, which featured participation from existing investors and key opinion leaders